Restricted accessResearch articleFirst published online 2014-11
Citrate Synthase Is a Novel In Vivo Matrix Metalloproteinase-9 Substrate That Regulates Mitochondrial Function in the Postmyocardial Infarction Left Ventricle
Aim: To evaluate the role of matrix metalloproteinase (MMP)-9 deletion on citrate synthase (CS) activity postmyocardial infarction (MI). Results: We fractionated left ventricle (LV) samples using a differential solubility-based approach. The insoluble protein fraction was analyzed by mass spectrometry, and we identified CS as a potential intracellular substrate of MMP-9 in the MI setting. CS protein levels increased in the insoluble fraction at day 1 post-MI in both genotypes (p<0.05) but not in the noninfarcted remote region. The CS activity decreased in the infarcted tissue of wild-type (WT) mice at day 1 post-MI (p<0.05), but this was not observed in the MMP-9 null mice, suggesting that MMP-9 deletion helps to maintain the mitochondrial activity post-MI. Additionally, inflammatory gene transcription was increased post-MI in the WT mice and attenuated in the MMP-9 null mice. MMP-9 cleaved CS in vitro, generating an ∼20 kDa fragment. Innovation: By applying a sample fractionation and proteomics approach, we were able to identify a novel MMP-9-related altered mitochondrial metabolic activity early post-MI. Conclusion: Our data suggest that MMP-9 deletion improves mitochondrial function post-MI. Antioxid. Redox Signal. 21, 1974–1985.
Get full access to this article
View all access options for this article.
References
1.
BarralJM, BroadleySA, SchaffarG, and HartlFU. Roles of molecular chaperones in protein misfolding diseases. Semin Cell Dev Biol, 15: 17–29, 2004.
2.
BayerE, BauerB, and EggererH. Evidence from inhibitor studies for conformational changes of citrate synthase. Eur J Biochem, 120: 155–160, 1981.
3.
BonarosN, SondermeijerH, SchusterM, RaufR, WangSF, SekiT, SkerrettD, ItescuS, and KocherAA. CCR3- and CXCR4-mediated interactions regulate migration of CD34+ human bone marrow progenitors to ischemic myocardium and subsequent tissue repair. J Thorac Cardiovasc Surg, 136: 1044–1053, 2008.
4.
BondDR, MesterT, NesboCL, Izquierdo-LopezAV, CollartFL, and LovleyDR. Characterization of citrate synthase from Geobacter sulfurreducens and evidence for a family of citrate synthases similar to those of eukaryotes throughout the Geobacteraceae. Appl Environ Microbiol, 71: 3858–3865, 2005.
5.
BorutaiteV. Mitochondria as decision-makers in cell death. Environ Mol Mutagen, 51: 406–416, 2010.
6.
BuggerH, ChemnitiusJM, and DoenstT. Differential changes in respiratory capacity and ischemia tolerance of isolated mitochondria from atrophied and hypertrophied hearts. Metabolism, 55: 1097–1106, 2006.
7.
ButlerGS, DeanRA, TamEM, and OverallCM. Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding. Mol Cell Biol, 28: 4896–4914, 2008.
8.
CauweB, MartensE, ProostP, and OpdenakkerG. Multidimensional degradomics identifies systemic autoantigens and intracellular matrix proteins as novel gelatinase B/MMP-9 substrates. Integr Biol (Camb), 1: 404–426, 2009.
9.
CauweB, MartensE, Van den SteenPE, ProostP, Van AelstI, BlockmansD, and OpdenakkerG. Adenylyl cyclase-associated protein-1/CAP1 as a biological target substrate of gelatinase B/MMP-9. Exp Cell Res, 314: 2739–2749, 2008.
10.
ChangJW, KimCS, KimSB, ParkSK, ParkJS, and LeeSK. C-reactive protein induces NF-kappaB activation through intracellular calcium and ROS in human mesangial cells. Nephron Exp Nephrol, 101: e165–e172, 2005.
11.
ChoiDH, KimEM, SonHJ, JohTH, KimYS, KimD, Flint BealM, and HwangO. A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. J Neurochem, 106: 405–415, 2008.
12.
CokerAR, PurvisA, BakerD, PepysMB, and WoodSP. Molecular chaperone properties of serum amyloid P component. FEBS Lett, 473: 199–202, 2000.
13.
CuadradoE, RosellA, Borrell-PagesM, Garcia-BonillaL, Hernandez-GuillamonM, Ortega-AznarA, and MontanerJ. Matrix metalloproteinase-13 is activated and is found in the nucleus of neural cells after cerebral ischemia. J Cereb Blood Flow Metab, 29: 398–410, 2009.
14.
de Castro BrasLE, DeleonKY, MaY, DaiQ, HakalaK, WeintraubST, and LindseyML. Plasma fractionation enriches post-myocardial infarction samples prior to proteomics analysis. Int J Proteomics, 2012: 397103, 2012.
15.
DeanRA, ButlerGS, Hamma-KourbaliY, DelbeJ, BrigstockDR, CourtyJ, and OverallCM. Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol Cell Biol, 27: 8454–8465, 2007.
16.
DucharmeA, FrantzS, AikawaM, RabkinE, LindseyM, RohdeLE, SchoenFJ, KellyRA, WerbZ, LibbyP, and LeeRT. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest, 106: 55–62, 2000.
17.
FrantzS, FraccarolloD, WagnerH, BehrTM, JungP, AngermannCE, ErtlG, and BauersachsJ. Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res, 57: 749–756, 2003.
18.
FrantzS, HuK, BayerB, GerondakisS, StrotmannJ, AdamekA, ErtlG, and BauersachsJ. Absence of NF-kappaB subunit p50 improves heart failure after myocardial infarction. FASEB J, 20: 1918–1920, 2006.
19.
GharacholouSM, AlexanderKP, ChenAY, WangTY, MelloniC, GiblerWB, PollackCVJr., OhmanEM, PetersonED, and RoeMT. Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative. Am Heart J, 159: 757–763, 2010.
20.
HoierB, NordsborgN, AndersenS, JensenL, NyboL, BangsboJ, and HellstenY. Pro- and anti-angiogenic factors in human skeletal muscle in response to acute exercise and training. J Physiol, 590(Pt 3): 595–606, 2012.
21.
HolmuhamedovEL, OberlinA, ShortK, TerzicA, and JahangirA. Cardiac subsarcolemmal and interfibrillar mitochondria display distinct responsiveness to protection by diazoxide. PLoS One, 7: e44667, 2012.
22.
HouZH, LuB, GaoY, CaoHL, YuFF, JingN, ChenX, CongXF, RoySK, and BudoffMJ. Matrix metalloproteinase-9 (MMP-9) and myeloperoxidase (MPO) levels in patients with nonobstructive coronary artery disease detected by coronary computed tomographic angiography. Acad Radiol, 20: 25–31, 2013.
23.
HussJM and KellyDP. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest, 115: 547–555, 2005.
24.
HwangIK, ParkSM, KimSY, and LeeST. A proteomic approach to identify substrates of matrix metalloproteinase-14 in human plasma. Biochim Biophys Acta, 1702: 79–87, 2004.
25.
IijimaT, MishimaT, AkagawaK, and IwaoY. Mitochondrial hyperpolarization after transient oxygen-glucose deprivation and subsequent apoptosis in cultured rat hippocampal neurons. Brain Res, 993: 140–145, 2003.
26.
IllmanSA, Keski-OjaJ, ParksWC, and LohiJ. The mouse matrix metalloproteinase, epilysin (MMP-28), is alternatively spliced and processed by a furin-like proprotein convertase. Biochem J, 375(Pt 1): 191–197, 2003.
27.
InfantinoV, ConvertiniP, CucciL, PanaroMA, Di NoiaMA, CalvelloR, PalmieriF, and IacobazziV. The mitochondrial citrate carrier: a new player in inflammation. Biochem J, 438: 433–436, 2011.
28.
KaplanRS, MayorJA, and WoodDO. The mitochondrial tricarboxylate transport protein. cDNA cloning, primary structure, and comparison with other mitochondrial transport proteins. J Biol Chem, 268: 13682–13690, 1993.
29.
KemiOJ, ArboI, HoydalMA, LoennechenJP, WisloffU, SmithGL, and EllingsenO. Reduced pH and contractility in failing rat cardiomyocytes. Acta Physiol, 188: 185–193, 2006.
30.
Lauer-FieldsJL, WhiteheadJK, LiS, HammerRP, BrewK, and FieldsGB. Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J Biol Chem, 283: 20087–20095, 2008.
31.
LindseyM, WedinK, BrownMD, KellerC, EvansAJ, SmolenJ, BurnsAR, RossenRD, MichaelL, and EntmanM. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation, 103: 2181–2187, 2001.
LlopisJ, McCafferyJM, MiyawakiA, FarquharMG, and TsienRY. Measurement of cytosolic, mitochondrial, and Golgi pH in single living cells with green fluorescent proteins. Proc Natl Acad Sci U S A, 95: 6803–6808, 1998.
34.
MaJ, GeJ, ZhangS, SunA, ShenJ, ChenL, WangK, and ZouY. Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res Cardiol, 100: 217–223, 2005.
35.
MaY, ChiaoYA, ZhangJ, ManiconeAM, JinYF, and LindseyML. Matrix metalloproteinase-28 deletion amplifies inflammatory and extracellular matrix responses to cardiac aging. Microsc Microanal, 18: 81–90, 2012.
36.
MaY, HaladeGV, ZhangJ, RamirezTA, LevinD, VoorheesA, JinYF, HanHC, ManiconeAM, and LindseyML. Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting m2 macrophage activation. Circ Res, 112: 675–688, 2013.
37.
MichaelLH, BallantyneCM, ZachariahJP, GouldKE, PociusJS, TaffetGE, HartleyCJ, PhamTT, DanielSL, FunkE, and EntmanML. Myocardial infarction and remodeling in mice: effect of reperfusion. Am J Physiol, 277: H660–H668, 1999.
38.
MoreiraJB, BecharaLR, BoziLH, JannigPR, MonteiroAW, DouradoPM, WisloffU, and BrumPC. High- versus moderate-intensity aerobic exercise training effects on skeletal muscle of infarcted rats. J Appl Physiol, 114: 1029–1041, 2013.
39.
ParkSM, HwangIK, KimSY, LeeSJ, ParkKS, and LeeST. Characterization of plasma gelsolin as a substrate for matrix metalloproteinases. Proteomics, 6: 1192–1199, 2006.
40.
PennaC, PerrelliMG, and PagliaroP. Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. Antioxid Redox Signal, 18: 556–599, 2013.
41.
RehrRB, ClarkeG, TatumJ, HirschJ, FatourosP, LowerR, and WetsteinL. Intracellular myocardial pH measured in vivo with sustained and reperfused coronary occlusion. Surgery, 102: 178–185, 1987.
42.
RemingtonS, WiegandG, and HuberR. Crystallographic refinement and atomic models of two different forms of citrate synthase at 2.7 and 1.7 A resolution. J Mol Biol, 158: 111–152, 1982.
43.
RoeMT, MessengerJC, WeintraubWS, CannonCP, FonarowGC, DaiD, ChenAY, KleinLW, MasoudiFA, McKayC, HewittK, BrindisRG, PetersonED, and RumsfeldJS. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol, 56: 254–263, 2010.
44.
SanbeA, TanonakaK, HanaokaY, KatohT, and TakeoS. Regional energy metabolism of failing hearts following myocardial infarction. J Mol Cell Cardiol, 25: 995–1013, 1993.
45.
SchenkS, MalN, FinanA, ZhangM, KiedrowskiM, PopovicZ, McCarthyPM, and PennMS. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells, 25: 245–251, 2007.
46.
SchildL, ReinheckelT, WiswedelI, and AugustinW. Short-term impairment of energy production in isolated rat liver mitochondria by hypoxia/reoxygenation: involvement of oxidative protein modification. Biochem J, 328(Pt 1): 205–210, 1997.
47.
ShenX, ZhengS, MetreveliNS, and EpsteinPN. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes, 55: 798–805, 2006.
48.
SrerePA. Controls of citrate synthase activity. Life Sci, 15: 1695–1710, 1974.
49.
SungMM, SchulzCG, WangW, SawickiG, Bautista-LopezNL, and SchulzR. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol, 43: 429–436, 2007.
50.
TangH, FuY, CuiY, HeY, ZengX, PloplisVA, CastellinoFJ, and LuoY. Fibrinogen has chaperone-like activity. Biochem Biophys Res Commun, 378: 662–667, 2009.
51.
TillmannsJ, CarlsenH, BlomhoffR, ValenG, CalvilloL, ErtlG, BauersachsJ, and FrantzS. Caught in the act: in vivo molecular imaging of the transcription factor NF-kappaB after myocardial infarction. Biochem Biophys Res Commun, 342: 773–774, 2006.
52.
UriaJA and Lopez-OtinC. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res, 60: 4745–4751, 2000.
53.
VanderveldeS, van LuynMJ, TioRA, and HarmsenMC. Signaling factors in stem cell-mediated repair of infarcted myocardium. J Mol Cell Cardiol, 39: 363–376, 2005.
54.
VuTH, ShipleyJM, BergersG, BergerJE, HelmsJA, HanahanD, ShapiroSD, SeniorRM, and WerbZ. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell, 93: 411–422, 1998.
55.
WilsonEM and SpinaleFG. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. Ann Med, 33: 623–634, 2001.
56.
YamashitaN, HoshidaS, OtsuK, AsahiM, KuzuyaT, and HoriM. Exercise provides direct biphasic cardioprotection via manganese superoxide dismutase activation. J Exp Med, 189: 1699–1706, 1999.
57.
YerburyJJ, KumitaJR, MeehanS, DobsonCM, and WilsonMR. alpha2-Macroglobulin and haptoglobin suppress amyloid formation by interacting with prefibrillar protein species. J Biol Chem, 284: 4246–4254, 2009.
58.
ZamilpaR, KanakiaR, Cigarroa IVJ, DaiQ, EscobarGP, MartinezH, JimenezF, AhujaSS, and LindseyML. CC chemokine receptor 5 deletion impairs macrophage activation and induces adverse remodeling following myocardial infarction. Am J Physiol Heart Circul Physiol, 300: H1418–H1426, 2011.
59.
ZamilpaR and LindseyML. Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol, 48: 558–563, 2010.
60.
ZamilpaR, LopezEF, ChiaoYA, DaiQ, EscobarGP, HakalaK, WeintraubST, and LindseyML. Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics, 10: 2214–2223, 2010.
61.
ZhaoYG, XiaoAZ, NewcomerRG, ParkHI, KangT, ChungLW, SwansonMG, ZhauHE, KurhanewiczJ, and SangQX. Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. J Biol Chem, 278: 15056–15064, 2003.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
